Nearly one in 20 people who had a SARS-CoV-2 infection go on to experience myalgic encephalomyelitis/chronic fatigue syndrome ...

The risk for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is increased following COVID-19, according to study findings.

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

The National Institute of Mental Health has awarded a significant grant of $1.5 million to Jianyang Du, PhD, of the ...

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

Indeed, a recent study published in the journal Arteriosclerosis, Thrombosis, and Vascular Biology found a prolonged ...

Vaccination prior to COVID-19 infection does not significantly affect neurologic symptoms in patients with long COVID.

Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, sore throat, loss of taste or smell, fatigue and body aches, headache, nausea ...

InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...

InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...

The COVID-19 vaccine confers protection against the development of post-COVID-19 conditions, particularly during the Delta and Omicron eras.